Erasmus School of Health Policy & Management
Visiting fellow | Health Technology Assessment (HTA)
- vangils@eshpm.eur.nl
More information
Work
- Renaud J.S.D. Heine, Ron H.J. Mathijssen, Floor A.J. Verbeek, Chantal Van Gils & Carin A. Uyl-de Groot (2024) - Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands Opens external - Value in Health, 27 (10), 1367-1372 - doi: 10.1016/j.jval.2024.06.003Opens external - [link]Opens external
- D. A. Young-Afat, , C. H. van Gils, H. J.G.D. van den Bongard, H. M. Verkooijen, S. A. Gernaat, M. L. Gregorowitsch, A. M. May, P. H. Peeters, C. C. van der Pol, A. J. Witkamp, R. M. Pijnappel, R. M. Bijlsma, W. Maarse, M. G. Ausems, P. J. van Diest, E. van der Wall, T. van Dalen, I. P. Burgmans, M. A. de Roos, R. C. van Doorn, I. O. Baas, B. van Ooijen & R. Koelemij (2017) - The Utrecht cohort for Multiple BREast cancer intervention studies and Long-term evaLuAtion (UMBRELLA): objectives, design, and baseline results Opens external - Breast Cancer Research and Treatment, 164 (2), 445-450 - doi: 10.1007/s10549-017-4242-4Opens external - [link]Opens external
- L Mohseninejad, Chantal van Gils, Carin Uyl - de Groot, E Buskens & TL (Talitha) Feenstra (2015) - Evaluation of Patient Registries Supporting Reimbursement Decisions: The Case of Oxaliplatin for Treatment of Stage III Colon Cancer Opens external - Value in Health, 18, 84-90 - doi: 10.1016/j.jval.2014.10.008Opens external - [link]Opens external
- Lucas Goossens, Ken Redekop & Chantal van Gils (2015) - Noncollapsibility and Censoring: What's the Bias in Estimating Effects on Survival? Opens external - Epidemiology, 26 (1), e1-e2 - doi: 10.1097/EDE.0000000000000197Opens external
- Chantal van Gils, Saskia de Groot, Siok Swan Tan, Ken Redekop, M Koopman, CJ Punt & Carin Uyl - de Groot (2014) - Real-world resource use and costs of adjuvant treatment for stage III colon cancer Opens external - European Journal of Cancer Care, 24 (3), 321-332 - doi: 10.1111/ecc.12154Opens external - [link]Opens external
- Naomi Linden, Chantal van Gils, CP Pescott, J Buter, MR Vergeer & Carin Uyl - de Groot (2014) - Real-world cost-effectiveness of cetuximab in locally advanced squamous cell carcinoma of the head and neck Opens external - European Archives of Oto-Rhino-Laryngology, 272 (8), 2007-2016 - doi: 10.1007/s00405-014-3106-3Opens external
- Chantal van Gils (2013) - Real-world cost-effectiveness Opens external - [link]Opens external
- Naomi Linden, Chantal van Gils, CP Pescott, J Buter & Carin Uyl - de Groot (2013) - Cetuximab in locally advanced squamous cell carcinoma of the head and neck: generalizability of EMR 062202-006 trial results Opens external - European Archives of Oto-Rhino-Laryngology, 271 (6), 1673-1678 - doi: 10.1007/s00405-013-2646-2Opens external - [link]Opens external
- Chantal van Gils, Saskia de Groot, Ken Redekop, M Koopman, CJA Punt & Carin Uyl - de Groot (2013) - Real-World Cost-Effectiveness of Oxaliplatin in Stage III Colon Cancer: A Synthesis of Clinical Trial and Daily Practice Evidence Opens external - Pharmacoeconomics (Print), 31 (8), 703-718 - doi: 10.1007/s40273-013-0061-6Opens external - [link]Opens external
- Margreet Franken, Chantal van Gils, JG (Jennifer G.) Gaultney, GO Delwel, W Goettsch, PC Huijgens, Adri Steenhoek, CJA Punt, M Koopman, Ken Redekop & Carin Uyl - de Groot (2013) - Practical feasibility of outcomes research in oncology: Lessons learned in assessing drug use and cost-effectiveness in The Netherlands Opens external - European Journal of Cancer, 49, 8-16 - doi: 10.1016/j.ejca.2012.06.010Opens external - [link]Opens external
- Chantal van Gils, M Koopman, L (Linda) Mol, Ken Redekop, Carin Uyl - de Groot & CJA Punt (2012) - Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands Opens external - Acta Oncologica, 51, 57-64 - doi: 10.3109/0284186X.2011.633930Opens external - [link]Opens external
- Margreet Franken, JG (Jennifer G.) Gaultney, Hedwig Blommestein, Siok Swan Tan, Chantal van Gils, PC Huijgens, Pieter Sonneveld, Ken Redekop & Carin Uyl - de Groot (2012) - Pilot outcomes research: effects and costs of bortezomib in relapsed or refractory multiple myeloma Opens external - [link]Opens external
- Siok Swan Tan, Chantal van Gils, Margreet Franken, Leona Hakkaart - van Roijen & Carin Uyl - de Groot (2010) - The Unit Costs of Inpatient Hospital Days, Outpatient Visits and Daycare Treatments in the Fields of Oncology and Hematology Opens external - Value in Health, 13 (6), 712-719 - doi: 10.1111/j.1524-4733.2010.00740.xOpens external - [link]Opens external
Master Thesis HEPLOpens external
- Level
- master
- Year Level
- master
- Year
- 2024
- Course Code
- GW4555M
Master Thesis HEOpens external
- Year Level
- master, master
- Year
- 2024
- Course Code
- GW4592M
